HS
VTYX

HighVista Strategies’s Ventyx Biosciences VTYX Stock Holding History

HighVista Strategies’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-23,583
Closed -$790K – 157
2023
Q1 		$790K Sell
23,583
-9,673
-29% -$376K 0.64% 49
2022
Q4 		$1.09M Buy
+33,256
New +$985K 0.65% 39

Other funds holding VTYX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

HighVista Strategies's VTYX Position: Q2 2023 in Review

HighVista Strategies sold out of Ventyx Biosciences (VTYX) in Q2 2023, closing a stake of 23,583 shares — an estimated $790K sold.

HighVista Strategies first reported a position in VTYX in Q4 2022 and held it in 2 quarters. The position peaked at $1.09M in Q4 2022. 150 funds tracked by Wall St. Rank hold VTYX as of Q2 2023.

  • HighVista Strategies reported no remaining Ventyx Biosciences position as of Q2 2023 after selling out during the quarter.
  • HighVista Strategies sold 23,583 Ventyx Biosciences shares in Q2 2023, an estimated $790K.
  • HighVista Strategies first reported a position in Ventyx Biosciences in Q4 2022 and held it in 2 quarters.
  • HighVista Strategies's Ventyx Biosciences position peaked at $1.09M in Q4 2022.
  • 150 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q2 2023.

Based on HighVista Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.